Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2 CAD | 0.00% |
|
0.00% | 0.00% |
21/06 | Telo Genomics Corp. announced that it has received CAD 0.65 million in funding | CI |
18/06 | Telo Genomics' Myeloma Test Accepted as Lab Developed Test by College of American Pathologists | MT |
Valuation
Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 10 | 1.996 | 9.89 | 25.65 | 21.27 | 20.99 |
Enterprise Value (EV) 1 | 9.935 | 2.256 | 9.009 | 22.05 | 18.62 | 18.35 |
P/E ratio | -1.97 x | -1.85 x | -5.78 x | -21.9 x | -9.95 x | -6.29 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | -2.22 x | -2.32 x | -7.23 x | -18.5 x | -9.09 x | -6.6 x |
EV / FCF | -5.52 x | 30.1 x | -7.85 x | -26.3 x | -18.1 x | -11.3 x |
FCF Yield | -18.1% | 3.32% | -12.7% | -3.8% | -5.52% | -8.85% |
Price to Book | -31.9 x | -1.91 x | 12.8 x | 7.54 x | 8.17 x | 8.03 x |
Nbr of stocks (in thousands) | 12,906 | 13,306 | 41,210 | 51,302 | 59,424 | 71,160 |
Reference price 2 | 0.7750 | 0.1500 | 0.2400 | 0.5000 | 0.3580 | 0.2950 |
Announcement Date | 15/11/18 | 28/10/19 | 28/10/20 | 28/10/21 | 27/09/22 | 30/10/23 |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA 1 | -4.484 | -0.9706 | -1.246 | -1.195 | -2.048 | -2.782 |
EBIT 1 | -4.609 | -1.054 | -1.311 | -1.257 | -2.105 | -2.816 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -4.695 | -1.074 | -1.242 | -1.07 | -2.11 | -2.821 |
Net income 1 | -4.695 | -1.074 | -1.242 | -1.07 | -2.11 | -2.821 |
Net margin | - | - | - | - | - | - |
EPS 2 | -0.3927 | -0.0812 | -0.0415 | -0.0228 | -0.0360 | -0.0469 |
Free Cash Flow 1 | -1.801 | 0.075 | -1.147 | -0.839 | -1.029 | -1.625 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 15/11/18 | 28/10/19 | 28/10/20 | 28/10/21 | 27/09/22 | 30/10/23 |
Balance Sheet Analysis
Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | 0.26 | - | - | - | - |
Net Cash position 1 | 0.07 | - | 0.88 | 3.6 | 2.65 | 2.64 |
Leverage (Debt/EBITDA) | - | -0.2684 x | - | - | - | - |
Free Cash Flow 1 | -1.8 | 0.07 | -1.15 | -0.84 | -1.03 | -1.62 |
ROE (net income / shareholders' equity) | -491% | 158% | 921% | -48% | -67.1% | -108% |
ROA (Net income/ Total Assets) | -163% | -190% | -114% | -31.4% | -39.4% | -61.1% |
Assets 1 | 2.887 | 0.5646 | 1.085 | 3.41 | 5.352 | 4.616 |
Book Value Per Share 2 | -0.0200 | -0.0800 | 0.0200 | 0.0700 | 0.0400 | 0.0400 |
Cash Flow per Share 2 | 0.0100 | 0 | 0.0200 | 0.0700 | 0.0500 | 0.0400 |
Capex 1 | 0.02 | - | - | 0.01 | 0.03 | 0.07 |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 15/11/18 | 28/10/19 | 28/10/20 | 28/10/21 | 27/09/22 | 30/10/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
0.00% | 1.04Cr | |
-40.08% | 763.4Cr | |
+7.17% | 360.74Cr | |
-0.06% | 236.46Cr | |
-24.56% | 186.16Cr | |
-18.47% | 173.77Cr | |
+3.28% | 91Cr | |
+18.17% | 76Cr | |
-10.48% | 68Cr | |
-0.60% | 29Cr |
- Stock Market
- Equities
- TELO Stock
- Financials Telo Genomics Corp.